peptideInjectableNot FDA-approvedResearch chemicalSold as a research chemical; no PubMed-indexed study of this specific salt form was identifiedNot an FDA-approved drug or dietary supplement in the US
BPC-157 ArginateBenefits, Dosage & Interactions
Also known as: Stable BPC
BPC-157 Arginate, also known as Stable BPC, is a modified, more stable form of Body Protective Compound-157 (BPC-157), a synthetic peptide derived from a protein found in the human stomach. Research on BPC-157 Arginate focuses on tissue recovery and cognition and mood.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
<30 min (rats, beagle dogs, intravenous — no human PK study)
Default unit
mcg
How to track BPC-157 Arginate doses
BPC-157 Arginate is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so BPC-157 Arginate is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when BPC-157 Arginate comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review BPC-157 Arginate alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
What is BPC-157 Arginate studied for?
What is BPC-157 Arginate?
BPC-157 Arginate, also known as Stable BPC, is a modified, more stable form of Body Protective Compound-157 (BPC-157), a synthetic peptide derived from a protein found in the human stomach. The 'arginate' modification refers to its salt form, which is designed to enhance its stability and bioavailability, particularly in acidic environments or when administered orally. BPC-157 is a pentadecapeptide, meaning it consists of 15 amino acids, and is a partial sequence of human gastric juice protein BPC. It has been extensively studied for its regenerative and protective effects in various tissues throughout the body.
While BPC-157 has traditionally been administered via injection, the development of BPC-157 Arginate aims to provide a more convenient and potentially equally effective oral delivery method. The rationale behind its creation is to allow the peptide to withstand the harsh acidic conditions of the stomach, thereby increasing its absorption and systemic availability. It is primarily researched for its potential in tissue repair and protective actions, making it of interest in the context of recovery from injury and various physiological stressors. (Source: PubChem)
What does the research say about BPC-157 Arginate?
Tap a section to expand.
The exact mechanisms of action for BPC-157 Arginate are believed to be similar to those of its parent compound, BPC-157, centering on its ability to promote tissue regeneration and exert protective effects. While the arginate modification primarily influences stability and absorption, the core biological activity is attributed to the peptide sequence itself.
One key mechanism involves its interaction with the nitric oxide (NO) system. BPC-157 has been shown to modulate nitric oxide synthesis and activity, which plays a crucial role in angiogenesis (formation of new blood vessels), blood flow regulation, and wound healing. By influencing the NO system, BPC-157 can improve circulation to injured areas, facilitating the delivery of nutrients and removal of waste products essential for repair.
Another significant mechanism is its influence on growth factors. Research suggests that BPC-157 enhances the expression of various growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). VEGF is vital for the development of new blood vessels, while bFGF is involved in cell proliferation, migration, and differentiation, all critical processes in tissue repair. It also appears to interact with the somatotropic axis indirectly, potentially enhancing the effects of growth hormone.
BPC-157 has also been noted for its anti-inflammatory properties. It can mitigate inflammatory responses, which are often detrimental to healing when prolonged or excessive. By reducing inflammation, the peptide helps to create a more favorable environment for tissue regeneration.
Furthermore, BPC-157 is believed to protect cells from damage and promote cell survival. It may stabilize cell membranes, scavenge free radicals, and protect against oxidative stress. These cytoprotective effects are important for maintaining tissue integrity and facilitating recovery from various forms of injury. It also appears to influence neurotransmitter systems, offering neuroprotective effects and potentially impacting mood and cognitive function, though this area requires further investigation. (Source: Examine.com, PubChem)
The potential benefits of BPC-157 Arginate are largely extrapolations from the extensive research on BPC-157, with the arginate form offering enhanced stability, particularly for oral administration. The primary focus of its benefits revolves around recovery and tissue protection.
* **Enhanced Wound Healing and Tissue Repair:** BPC-157 Arginate is studied for its ability to accelerate the healing of various tissues, including muscles, tendons, ligaments, bones, and gastrointestinal tract. This includes aiding in the repair of tendon-to-bone healing, ligament injuries, and even spinal cord injuries in animal models. Its influence on angiogenesis and growth factors likely plays a key role here.
* **Gastrointestinal Protection and Healing:** A significant area of research for BPC-157 is its potent gastroprotective effects. It has been shown to protect the gastric lining from damage induced by various agents and to promote the healing of ulcers, possibly by enhancing mucosal integrity and blood flow. The arginate form, with its increased stability in acidic environments, is particularly relevant for addressing gastrointestinal issues.
* **Anti-inflammatory Effects:** The peptide exhibits anti-inflammatory properties, which can help reduce swelling and pain associated with injuries and chronic inflammatory conditions. By modulating inflammatory responses, it creates a more conducive environment for tissue repair.
* **Neurological Protection:** Emerging research suggests BPC-157 may offer neuroprotective effects, including potential benefits for brain injury, nerve damage, and even some psychiatric conditions by modulating neurotransmitter systems. This area requires more human research.
* **Cardioprotective Effects:** Studies indicate a potential role in protecting the heart and blood vessels, particularly in models of heart damage or ischemia. This could involve improving blood flow and reducing oxidative stress.
It is important to note that while animal studies show promising results across these areas, human clinical trials are still limited, and more research is needed to fully establish the efficacy and safety of BPC-157 Arginate for these conditions. (Source: Examine.com, PubChem)
The evidence for the effects of BPC-157 Arginate, and BPC-157 generally, primarily stems from a substantial body of preclinical research. Numerous animal studies, including those on rats, mice, and rabbits, have investigated its regenerative and protective properties across various organ systems. These studies have consistently demonstrated positive outcomes, particularly in models of injury and inflammation.
For instance, studies in rodents have shown BPC-157 to accelerate the healing of transected Achilles tendons, quadriceps muscles, and crush injuries of nerves. It has also been effective in promoting bone fracture healing and ligament repair. In terms of gastrointestinal health, extensive research has highlighted its ability to heal various types of ulcers (e.g., gastric, duodenal, esophageal) and protect the gut lining from damage induced by drugs like NSAIDs or stress.
Neuroprotective effects have been observed in animal models of spinal cord injury, traumatic brain injury, and stroke, where BPC-157 has been shown to promote nerve regeneration and reduce neuronal damage. Cardioprotective effects, including mitigating damage from heart attack-like conditions and improving recovery, have also been documented in preclinical studies.
While the preclinical data is robust and highly suggestive of therapeutic potential, human clinical trials are less numerous and more recent for BPC-157, and even more scarce specifically for the arginate form. The transition from animal models to human clinical application is ongoing. Without extensive human trials, the full scope of its efficacy and safety in humans cannot be definitively confirmed. Therefore, evidence for BPC-157 Arginate's benefits in humans is largely based on extrapolation from its parent compound and preclinical data. (Sources: PubMed reviews, Examine.com)
Due to the limited human clinical trial data specifically on BPC-157 Arginate, comprehensive information regarding its side effects in humans is not yet well-established. Side effects, if any, are generally extrapolated from the broader research on BPC-157.
In animal studies, BPC-157 has generally shown a favorable safety profile with few reported adverse effects, even at high doses. However, extrapolation from animal data to humans does not guarantee identical outcomes.
Potential mild side effects that might theoretically occur, based on general peptide administration or anecdotal reports, could include:
* Localized irritation at the injection site (if administered via injection).
* Mild gastrointestinal discomfort (if administered orally).
* Headache or fatigue (less common).
Because BPC-157 Arginate can influence various physiological systems, including growth factors and angiogenesis, there is theoretical concern that it might influence the growth of existing tumors or precancerous cells. However, this remains speculative and has not been definitively demonstrated. (Source: Limited human data, animal studies on BPC-157).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
As with any novel compound with limited human clinical trial data, several warnings are pertinent to BPC-157 Arginate.
* **Lack of Extensive Human Data:** The most significant warning is the limited number of comprehensive human clinical trials specifically for BPC-157 Arginate. Most available information is derived from animal studies or anecdotal reports. This means its full safety profile and efficacy in humans are not yet fully understood.
* **Regulatory Status:** BPC-157 Arginate is not approved by major regulatory bodies (such as the FDA in the United States) for human therapeutic use. Its quality, purity, and formulation may vary significantly between suppliers, which poses risks.
* **Potential for Undesired Interactions:** While no specific drug interactions are well-documented, the peptide's broad influence on healing, growth factors, and inflammation means it could potentially interact with other medications or supplements, especially those affecting immune function, blood clotting, or cell growth.
* **Theoretical Concerns Regarding Cancer:** Given BPC-157's ability to promote cell growth and angiogenesis, there's a theoretical concern it could accelerate the growth of existing cancers or contribute to the progression of precancerous conditions. Individuals with a history of cancer or who are at high risk should exercise extreme caution and seek medical advice.
* **Pregnancy and Breastfeeding:** Due to the lack of safety data, BPC-157 Arginate should not be used by pregnant or breastfeeding individuals.
* **Use in Children:** The safety and efficacy in pediatric populations have not been established. It should not be used in children.
* **Underlying Medical Conditions:** Individuals with any pre-existing medical conditions, particularly autoimmune disorders, cardiovascular disease, or gastrointestinal bleeding, should consult a healthcare professional. (Source: General scientific caution for novel compounds, absence of comprehensive human data).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Specific contraindications for BPC-157 Arginate are not officially established due to the limited human clinical trial data and regulatory status. However, based on its proposed mechanisms of action and general medical principles, the following situations would typically be considered contraindications or necessitate extreme caution:
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to BPC-157 or any components of BPC-157 Arginate formulations should avoid its use.
* **Active Cancer or History of Cancer:** Due to BPC-157's influence on cell proliferation and angiogenesis, its use is generally contraindicated in individuals with active cancer or a history of cancer. There is a theoretical risk that it could promote tumor growth or recurrence.
* **Pregnancy and Breastfeeding:** There is no safety data for BPC-157 Arginate during pregnancy or lactation. Therefore, it is contraindicated in these populations.
* **Children:** The safety and efficacy in pediatric populations have not been studied, making its use contraindicated in children.
* **Undiagnosed Mass or Lesion:** Any suspicious, undiagnosed growth, lesion, or mass should be thoroughly investigated before considering BPC-157 Arginate, due to the theoretical concern regarding cell proliferation.
* **Severe Underlying Medical Conditions:** While not an absolute contraindication, individuals with severe cardiovascular disease, advanced kidney or liver disease, or active bleeding disorders should proceed with extreme caution and under strict medical supervision, if at all. (Source: General medical principles, theoretical concerns based on BPC-157 research).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited research on BPC-157 Arginate in humans, specific drug-drug or supplement-supplement interactions are not well-documented. However, based on its purported effects and general pharmacological principles, caution should be exercised when combining it with certain substances.
* **Immunosuppressants:** BPC-157 may modulate immune responses. Combining it with immunosuppressant medications could theoretically alter their effects. Conversely, in some models, BPC-157 has shown immunomodulatory effects that might be beneficial, but specific interactions require careful study.
* **Anticoagulants/Antiplatelet Agents:** While not directly studied, the potential for BPC-157 to influence blood vessel formation (angiogenesis) and blood flow could theoretically interact with medications that affect blood clotting, such as warfarin, aspirin, or direct oral anticoagulants. This could alter the risk of bleeding or clotting.
* **Drugs Affecting Cell Proliferation (e.g., Chemotherapy):** Given the theoretical concern that BPC-157 could influence cell growth, combining it with chemotherapy agents or other drugs designed to inhibit cell proliferation should be approached with extreme caution, as it could potentially interfere with their mechanism of action or efficacy.
* **Growth Factors and Hormones:** BPC-157 is thought to interact with various growth factors and potentially influence hormonal axes. Combining it with exogenous growth factors or hormones without medical guidance could lead to unpredictable effects.
* **Alcohol:** As BPC-157 is being investigated for gastroprotective properties, consuming alcohol, which is a known gastric irritant, might counteract some of its potential benefits, especially when using the oral arginate form for gut healing.
It is crucial to emphasize that these are largely theoretical considerations based on the known science of BPC-157. Always consult a healthcare professional before combining BPC-157 Arginate with any other medication, supplement, or substance. (Source: Theoretical considerations based on BPC-157 mechanisms, general pharmacology).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for BPC-157 Arginate, like its parent compound BPC-157, is user-directed and must be set by a licensed clinician. However, general considerations for administration often revolve around the goal of use and the route of administration.
For **oral administration**, particularly with the arginate form designed for enhanced stability in the digestive tract, it is generally recommended to be taken on an empty stomach (either before a meal or several hours after) to potentially optimize absorption without interference from food. This is a common practice for peptides and other compounds that might be degraded by digestive enzymes or bind to food components. However, some sources suggest it can be taken with or without food for convenience, especially if gastrointestinal sensitivity is a concern. The stability of the arginate form aims to mitigate some of these issues.
For **injectable administration** (though BPC-157 Arginate is primarily developed for oral use, BPC-157 is commonly injected):
* **Subcutaneous (SC) injection:** Often administered once or twice daily, typically to the abdominal area. There is no strict timing requirement relative to meals.
* **Intramuscular (IM) injection:** Less common for general use but may be used when targeting specific muscle injuries. Timing is typically user-directed.
Regardless of the route, consistency in timing is often emphasized to maintain steady levels, if a clinician determines that this is a beneficial strategy. The half-life of BPC-157 in rodents is approximately 4-6 hours, so multiple daily doses are sometimes employed to maintain therapeutic concentrations. However, the arginate form's stability and potential for extended action due to slower degradation might influence optimal dosing frequency, though specific human data is lacking.
The user-directed dose for BPC-157 Arginate must be set by a licensed clinician. (Source: Limited anecdotal reports, preclinical studies on BPC-157 pharmacokinetics, general peptide administration practices).
What interacts with BPC-157 Arginate?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about BPC-157 Arginate
BPC-157 Arginate is a modified, more stable salt form of BPC-157. The arginate modification is intended to enhance its stability, particularly in acidic environments like the stomach, making it potentially more effective for oral administration compared to regular BPC-157 which is often degraded in the gut.
No, BPC-157 Arginate is not approved by the FDA (or similar regulatory bodies globally) for human therapeutic use. It is currently considered an investigational compound, and its sale and use are not regulated for medical purposes.
The timeframe for observing results with BPC-157 Arginate can vary widely depending on the individual, the condition being addressed, and the severity of the injury. Based on preclinical studies and anecdotal reports, some individuals may perceive effects within a few days to a couple of weeks, particularly for acute injuries or gastrointestinal issues, while more chronic or severe conditions may require longer durations of use. Consistent use as directed by a clinician is typically advised.
While BPC-157 Arginate is not approved for human use, its parent compound, BPC-157, has gained attention in athletic circles for its potential to accelerate recovery from injuries. However, it is important to note that BPC-157 is listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of peptide hormones, growth factors, and related substances. Athletes should be aware of anti-doping regulations. (Source: WADA).
The precise half-life of BPC-157 Arginate specifically in humans is not well-established. However, the half-life of its parent compound, BPC-157, in rodent models is reported to be approximately 4-6 hours. The arginate modification aims for increased stability and potentially prolonged activity, but concrete human pharmacokinetic data is limited.
As a peptide, BPC-157 Arginate can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers BPC-157 Arginate with no sign-up.
BPC-157 Arginate is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether BPC-157 Arginate fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to BPC-157 Arginate. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for BPC-157 Arginate varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of BPC-157 Arginate depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like BPC-157 Arginate the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- WADA Prohibited List(opens in a new tab)World Anti-Doping Agency · wada-ama.org/en/prohibited-list
Verify at
Publisher search links for BPC-157 Arginate. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on BPC-157 Arginate?
Plain-text summary, safe to quote verbatim:
BPC-157 Arginate, also known as Stable BPC, is a modified, more stable form of Body Protective Compound-157 (BPC-157), a synthetic peptide derived from a protein found in the human stomach. Research on BPC-157 Arginate focuses on tissue recovery and cognition and mood.
Source: DoseRoutine — https://doseroutine.com/library/bpc-157-arginate
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). BPC-157 Arginate — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/bpc-157-arginate
What compounds are similar to BPC-157 Arginate?
Others in the peptide category or studied for the same goals.
Which goals is BPC-157 Arginate used for?
Other compounds studied for the same benefits as BPC-157 Arginate.
Recovery & Healing
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.